A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when
administered concurrently with an ARB, is designed to inhibit recruitment of monocytes
implicated in the inflammatory chemokine environment of chronic disease. The purpose of this
pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200
120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult
patients with biopsy-proven FSGS who are being treated with an ARB.